H
Hartmut Stuetzer
Researcher at University of Cologne
Publications - 15
Citations - 883
Hartmut Stuetzer is an academic researcher from University of Cologne. The author has contributed to research in topics: Head and neck cancer & Intensive care unit. The author has an hindex of 10, co-authored 15 publications receiving 830 citations.
Papers
More filters
Journal ArticleDOI
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
S. Staar,Volker Rudat,Hartmut Stuetzer,Andreas Dietz,Peter Volling,Michael Schroeder,Michael Flentje,Hans Edmund Eckel,Rolf-Peter Mueller +8 more
TL;DR: With accelerated radiotherapy, the efficiency of simultaneously given chemotherapy may be not as high as expected when compared to standard fractionated RT and should be given in radiotherapy regimen only with strong hematologic indication.
Journal ArticleDOI
Postcatheterization pseudoaneurysm : Results of US-guided percutaneous thrombin injection in 240 patients
TL;DR: US-guided percutaneous thrombin injection enables successful, safe management of postcatheterization pseudoaneurysms.
Journal ArticleDOI
Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: Updated results of a randomized multicentric trial in advanced head-and-neck cancer
Robert Semrau,Rolf-Peter Mueller,Hartmut Stuetzer,Susanne Staar,Ursula Schroeder,Orlando Guntinas-Lichius,Martin Kocher,Hans Theodor Eich,Andreas Dietz,Michael Flentje,Volker Rudat,P. Volling,Michael Schroeder,Hans Edmund Eckel +13 more
TL;DR: Hyperfractionated-accelerated RCT is superior to hf-acc RT in oropharyngeal carcinomas and overall survival shows a benefit for RCT, however, the benefit in SLC and OS is not seen in hypopharyngeAL carcinomas.
Journal ArticleDOI
Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients.
Orlando Guntinas-Lichius,Matthias Kreppel,Hartmut Stuetzer,Robert Semrau,Hans Edmund Eckel,Rolf-Peter Mueller +5 more
TL;DR: In this paper, the authors assess the single and multimodal treatment results and prognostic factors for sinonasal carcinoma, and calculate the 5-year overall survival (OS), disease-specific survival (DSS), local control (LC), and disease-free survival (DFS) in 229 patients treated from 1967 to 2003 were calculated.
Journal ArticleDOI
Daily assessment of organ dysfunction and survival in intensive care unit cardiac surgical patients.
Khosro Hekmat,Axel Kroener,Hartmut Stuetzer,Robert H. G. Schwinger,Sandra Kampe,Gerardus Bennink,Uwe Mehlhorn +6 more
TL;DR: The new 10-variable risk index performs very well, with calibration and discrimination very high, better than general severity systems; and it is an appropriate tool for daily risk stratification in ICU cardiac surgery patients.